T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2301
Geron
GERN
$1.01B
| $226K | ﹤0.01% |
59,900
-18,200
| -23% | -$61.8K |
|
|
CNBKA
2302
DELISTED
Century Bancorp Inc/Mass
CNBKA
| $226K | ﹤0.01% |
5,700
-150
| -3% | -$5.91K |
|
|
SRDX
2303
DELISTED
Surmodics
SRDX
| $225K | ﹤0.01% |
+8,650
| New | +$206K |
|
2304
CBIZ
CBZ
$2.96B
| $223K | ﹤0.01% |
23,949
+2,393
| +11% | +$20.9K |
|
2305
Peoples Bancorp
PEBO
$1.48B
| $222K | ﹤0.01% |
9,395
| – | – |
|
|
DTSI
2306
DELISTED
DTS, Inc.
DTSI
| $222K | ﹤0.01% |
6,522
| – | – |
|
|
CTO
2307
CTO Realty Growth
CTO
$819M
| $221K | ﹤0.01% |
13,631
-737
| -5% | -$11.4K |
|
2308
Hurco Companies Inc
HURC
$144M
| $221K | ﹤0.01% |
6,700
-400
| -6% | -$13.7K |
|
2309
Option Care Health
OPCH
$3.57B
| $220K | ﹤0.01% |
12,400
+3,275
| +36% | +$71.5K |
|
|
ALJ
2310
DELISTED
Alon USA Energy Inc
ALJ
| $219K | ﹤0.01% |
+13,204
| New | +$175K |
|
|
XNPT
2311
DELISTED
XENOPORT, INC.
XNPT
| $219K | ﹤0.01% |
30,700
-9,900
| -24% | -$76.8K |
|
|
HEES
2312
DELISTED
H&E Equipment Services
HEES
| $217K | ﹤0.01% |
8,700
-158,350
| -95% | -$3.56M |
|
2313
Westwood Holdings Group
WHG
$183M
| $217K | ﹤0.01% |
3,600
| – | – |
|
|
SGYP
2314
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $217K | ﹤0.01% |
47,000
| – | – |
|
|
GES
2315
DELISTED
Guess Inc
GES
| $216K | ﹤0.01% |
11,620
-7,800
| -40% | -$147K |
|
|
SEAC
2316
DELISTED
Seachange International Inc
SEAC
| $216K | ﹤0.01% |
1,378
+200
| +17% | +$29.3K |
|
2317
AngioDynamics
ANGO
$651M
| $212K | ﹤0.01% |
11,932
| – | – |
|
2318
AMES National
ATLO
$281M
| $211K | ﹤0.01% |
8,500
+550
| +7% | +$13.5K |
|
2319
Mastech Digital
MHH
$92.7M
| $210K | ﹤0.01% |
46,184
| – | – |
|
2320
TriCo Bancshares
TCBK
$1.84B
| $210K | ﹤0.01% |
8,700
| – | – |
|
2321
Western New England Bancorp
WNEB
$282M
| $210K | ﹤0.01% |
27,200
| – | – |
|
2322
Harte-Hanks
HHS
$18.6M
| $209K | ﹤0.01% |
2,675
| – | – |
|
|
FFG
2323
DELISTED
FBL Financial Group
FFG
| $209K | ﹤0.01% |
+3,374
| New | +$192K |
|
2324
PetMed Express
PETS
$43M
| $208K | ﹤0.01% |
12,600
| – | – |
|
2325
Tejon Ranch
TRC
$441M
| $208K | ﹤0.01% |
8,106
-2,163
| -21% | -$54K |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.